Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.
about
Trafficking of Sendai virus nucleocapsids is mediated by intracellular vesiclesSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusProtective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.Combining single RNA sensitive probes with subdiffraction-limited and live-cell imaging enables the characterization of virus dynamics in cells.Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in miceA respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.Live bivalent vaccine for parainfluenza and influenza virus infections.Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1Structure and function of respiratory syncytial virus surface glycoproteins.Function of the small hydrophobic protein of J paramyxovirus.Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.Nonsegmented negative-strand viruses as vaccine vectors.Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging studyAn evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in childrenSendai virus-based RSV vaccine protects African green monkeys from RSV infection.Reduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient miceCarriers for the delivery of a vaccine against respiratory syncytial virus.Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein.Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications.Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BRecombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenicInfluence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.Mouse models for the study of mucosal vaccination against otitis media.Sendai virus as a backbone for vaccines against RSV and other human paramyxovirusesSendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsTargeting RSV with vaccines and small molecule drugs.Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gutRespiratory syncytial virus: immunopathology and control.RNA-based viral vectors.Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice.Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice.
P2860
Q27325499-58554CE6-0841-4CF0-BADE-ECFD507CB294Q28067143-6AF95069-1ED8-427B-94A6-EB60AC0CA179Q30485791-D2393A7C-A3CC-43A9-B556-9BE14E7516AFQ30570055-A7A923D2-6F44-4668-931D-72FCF7FC5622Q33558419-FA01E304-D8B5-4278-86C2-ADA9E050B0EFQ33690612-B479E232-52BF-4A10-BDA5-0412468AB279Q33776507-71361288-A0D7-4A52-B940-0490EB90C0ECQ33788756-8EEFEB1E-BB70-4AA7-B58D-10499E77FFC5Q33964142-81432A68-B900-47E2-8361-02F556FBB437Q34100215-B2F234B5-0F05-4C98-B4DA-406677173B6FQ34175747-734D4440-ADCF-41CC-B813-450B42AB3E3EQ34414405-E806D357-89DE-4D59-86FB-3A12EBC65AAAQ34457944-19F60ECE-25C3-4A73-BACE-FFEC3F7C4927Q35122827-B5CF64F3-0A2A-42E3-A40D-2037E7ACE3E4Q35139219-49499D89-855A-4EDA-ACB8-1B5E480150F0Q35188476-BA50E716-4D0E-427D-BE51-68F30E47C0EBQ35487966-9E7E4EEB-67E9-4F9E-9770-FB764A090837Q35595950-050AEA53-EC1A-4E6F-95E5-C0F317E6BB61Q35667184-4E454FA4-25C1-4220-BD68-EB4557883D43Q35940739-341DFE81-3547-40F1-B8A7-8356A93F5F5EQ36194078-85121B2F-01DA-4F5C-B388-A79D23CDAE87Q36315159-35D3500E-20A6-4D29-AA2B-D3A0FFC1B628Q36315473-0DA37B23-4D36-4E44-A166-A72D18CAE5F6Q36377208-D7FC70C2-1992-4A59-9CD3-85178E87B504Q36453608-B35AECF5-D251-4EDD-995F-D9E231B8B104Q36823131-B57AD398-BFFE-406C-864E-C8A5E104EB76Q36827280-E806591E-C2C9-48AA-9406-9944376F65D6Q37071608-3DFF5F4C-BCAE-4E43-813B-308DFEB912C3Q37093093-AD0D117D-5C51-4B83-B161-1592E4789E88Q37118707-22DAE888-3229-40DF-B318-124F16DC5924Q37308711-82EB5CAB-E14A-4DB5-9CB7-379704DB4899Q37328584-AFA05DAE-9AF1-4BD8-8C08-70A0E28FB8C3Q37348134-B6700CC3-EBCF-409B-945D-F904E980ED94Q37412509-06051E1F-879C-4D9D-A6F4-D6B3B8263408Q37615056-0179F666-5626-4206-97B4-DAA5EAC42E06Q37754763-C4C201AD-6A6F-47AC-9856-B6E8EC177C7AQ38266413-FF281EE7-C002-408E-97BB-0A518E061FDDQ39868227-BC88128C-6351-42A9-BCEE-1EEE92C92DF7Q40273775-5FD4E0DD-066B-4AC8-8AFD-8E65273E757AQ40409972-928E0FBA-BF9A-4477-9D8C-C420BBB7E9D9
P2860
Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Recombinant Sendai virus expre ...... immune protection against RSV.
@en
type
label
Recombinant Sendai virus expre ...... immune protection against RSV.
@en
prefLabel
Recombinant Sendai virus expre ...... immune protection against RSV.
@en
P2093
P2860
P1433
P1476
Recombinant Sendai virus expre ...... immune protection against RSV.
@en
P2093
Allen Portner
Brita Brown
Cecilia Prouser
Chris Coleclough
Julia L Hurwitz
Karen S Slobod
Kelli Boyd
Ruth A Scroggs
Sateesh Krishnamurthy
Toru Takimoto
P2860
P304
P356
10.1128/JVI.78.11.6043-6047.2004
P407
P577
2004-06-01T00:00:00Z